Bionova Scientific, a contract development and manufacturing organisation (CDMO), is entering the advanced therapy manufacturing space.
The company is installing its third FlexFactory manufacturing platform from Cytiva to meet the surging demand for advanced therapies, while maintaining its core monoclonal antibody (mAb) business.
Bionova will also use Cytiva’s Fast Trak process development services to help advance its entry into genomic medicines.
Fabio Fonseca, PhD, Senior Director, pDNA Process Development, Bionova Scientific, says: “Using Cytiva’s end-to-end solutions, we’ll have an exceptional platform to support the manufacture of genomic medicines."
"Together with our team and technology stack, we are well-positioned to deliver plasmid DNA with speed, quality and patient safety.”
Ludovic Brellier, President of Hardware Solutions, Cytiva, adds: “Our true value lies in our deep process expertise in accelerating our customers’ process development through to commercial manufacturing."
"Having the flexibility and support to scale while meeting strict regulatory compliance will help Bionova develop a competitive edge in a growing market.”
The FlexFactory platform for advanced therapies offers substantial benefits that reduce business risks, increase operational speed, facilitate faster product ramp-up and enhance flexibility.
Its built-in compliance features and robust quality controls help to improve regulatory adherence and minimise production issues, whereas its modular set-up allows rapid adaptation to market shifts.
Cytiva’s Fast Trak process development services will help Bionova to accelerate the company's molecules through clinical development.
